The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 04, 2020
Filed:
Sep. 09, 2016
Applicant:
The General Hospital Corporation, Boston, MA (US);
Inventors:
Xi Ren, Malden, MA (US);
Harald C. Ott, Wenham, MA (US);
Assignee:
The General Hospital Corporation, Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/00 (2006.01); C12N 5/02 (2006.01); A61K 35/32 (2015.01); C07K 14/00 (2006.01); C12N 5/071 (2010.01); C12M 3/00 (2006.01); C12M 1/36 (2006.01); C12M 1/12 (2006.01); C07K 14/475 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0697 (2013.01); C12M 21/08 (2013.01); C12M 25/14 (2013.01); C12M 41/48 (2013.01); C12N 5/0688 (2013.01); C07K 14/475 (2013.01); C12N 2500/02 (2013.01); C12N 2500/25 (2013.01); C12N 2501/01 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/135 (2013.01); C12N 2501/15 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/17 (2013.01); C12N 2501/39 (2013.01); C12N 2501/415 (2013.01); C12N 2502/1388 (2013.01); C12N 2502/27 (2013.01); C12N 2502/28 (2013.01); C12N 2506/45 (2013.01); C12N 2533/92 (2013.01);
Abstract
A method for vascular regeneration comprises delivering endothelial cells to a lung scaffold, delivering perivascular cells to the lung scaffold, and providing a multiphase culture program to the scaffold. The multiphase culture program comprises a first phase including delivering an angiogenic medium, e.g., having 40-100 ng/ml of pro-angiogenic factors, and a second phase including delivering a stabilization medium, e.g., having 0.5-2% of serum and 1-20 ng/ml of angiogenic factors.